|
Status |
Public on Dec 01, 2020 |
Title |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (RNA-Seq) |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Genome-wide gene expression changes in response to iEZH treatment in HT and SUDHL6 cells using RNA sequencing (RNA-seq).
|
|
|
Overall design |
Expression profiling by RNA-seq of HT and SUDHL6 cell lines after 96 hours of treatment with iEZH.
|
|
|
Contributor(s) |
Trojer P, Garapaty S, Lan F, Hatton C, Bryant B |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Aug 29, 2012 |
Last update date |
Dec 01, 2020 |
Contact name |
Barbara M Bryant |
E-mail(s) |
barbara.bryant@constellationpharma.com
|
Organization name |
Constellation Pharmaceuticals
|
Street address |
215 First Street
|
City |
Cambridge |
State/province |
MA |
ZIP/Postal code |
02142 |
Country |
USA |
|
|
Platforms (1) |
GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
Samples (8)
|
|
This SubSeries is part of SuperSeries: |
GSE40476 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor |
|
Relations |
BioProject |
PRJNA174129 |
SRA |
SRP015323 |